amycretin vs cagrilintide

NCT06064006 · Phase 2 · completed

The study was randomized, quadruple-masked, and placebo-controlled, with 125 participants, providing a meaningful controlled design. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

This trial's registered primary endpoint was safety (treatment-emergent adverse events); the figures shown are its prespecified secondary weight-change endpoints as published in The Lancet.

NCT03856047 · Phase 2 · completed

The trial randomized participants to five active doses, a pooled placebo, and an active liraglutide comparator arm, with quadruple-blinding (participant, care provider, investigator, and outcomes assessor all masked) and roughly 100 participants per arm. The primary endpoint, percent change in body weight at 26 weeks, is the regulator-accepted physiological measure for obesity trials, and every cagrilintide dose showed a statistically significant weight-loss advantage over placebo (p-values ranging from 0.0002 to <.0001), so the primary comparison was clearly met in the favorable direction.

NCT06542874 · Phase 2 · completed

This was a randomized, quadruple-blinded, placebo-controlled trial with 448 participants and a validated diabetes disease-control endpoint (HbA1c). The primary comparison was clearly positive, with HbA1c reductions of up to 1.8 percentage points (subcutaneous) and 1.5 points (oral) that were statistically significant against placebo.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.